Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry

被引：0

作者：

de Swart, Louise ^{[1
]}

Smith, Alex ^{[2
]}

Fenaux, Pierre ^{[3
]}

Symeonidis, Argyris ^{[4
]}

Hellstrom-Lindberg, Eva ^{[5
]}

Sanz, Guillermo ^{[6
]}

Cermak, Jaroslav ^{[7
]}

Georgescu, Otilia ^{[8
]}

Germing, Ulrich ^{[9
]}

MacKenzie, Marius ^{[1
]}

Beyne-Rauzy, Odile ^{[10
]}

Malcovati, Luca ^{[11
]}

Stauder, Reinhard ^{[12
]}

Droste, Jackie ^{[1
]}

Bowen, David ^{[13
]}

de Witte, Theo ^{[1
]}

机构：

[1] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands

[2] Univ York, Epidemiol & Genet Unit, York YO10 5DD, N Yorkshire, England

[3] Hop Avicenne, Serv Hematol Clin, F-93009 Bobigny, France

[4] Greek Myeloma Study Grp, Athens, Greece

[5] Karolinska Inst, Dept Med, Div Hem, Stockholm, Sweden

[6] Hosp Univ La Fe, Dept Hematol, Valencia, Spain

[7] Inst Hematol & Blood Transfus, CR-12820 Prague, Czech Republic

[8] Fundeni Clin Inst, Bucharest, Romania

[9] Univ Klin Dusseldorf, Dusseldorf, Germany

[10] GFM, Bobigny, France

[11] Univ Pavia, Carattere Sci Policlin San Matteo, Fdn Ist Ricovero & Cura, I-27100 Pavia, Italy

[12] Innsbruck Med Univ, Dep Internal Med Haematol & Oncol 5, Innsbruck, Austria

[13] Leeds Teaching Hosp, St Jamess Inst Oncol, Leeds, W Yorkshire, England

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1201 / 1202

页数：2

共 50 条

[41] Phase II Study of Targeted Subcutaneous (SC) Bortezomib for Patients with Low- or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndrome (MDS) with Evidence of NF-κB Activation
Randhawa, Jasleen K.
Jabbar, Kausar Jabeen
Kadia, Tapan
Borthakur, Gautam
Pemmaraju, Naveen
Daver, Naval
Kantarjian, Hagop M.
Cortes, Jorge E.
Hearn, Katherine
Bueso-Ramos, Carlos E.
Garcia-Manero, Guillermo
[J]. BLOOD, 2014, 124 (21)
[42] Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry
Hoeks, Marlijn
Yu, Ge
Langemeijer, Saskia
Crouch, Simon
de Swart, Louise
Fenaux, Pierre
Symeonidis, Argiris
Cermak, Jaroslav
Hellstrom-Lindberg, Eva
Sanz, Guillermo
Stauder, Reinhard
Holm, Mette Skov
Mittelman, Moshe
Madry, Krzysztof
Malcovati, Luca
Tatic, Aurelia
Almeida, Antonio Medina
Germing, Ulrich
Savic, Aleksandar
Simec, Njetocka Gredelj
Culligan, Dominic
Itzykson, Raphael
Guerci-Bresler, Agnes
Slama, Borhane
van de Loosdrecht, Arjan
van Marrewijk, Corine
Droste, Jackie
Blijlevens, Nicole
van Kraaij, Marian
Bowen, David
de Witte, Theo
Smith, Alex
[J]. HAEMATOLOGICA, 2020, 105 (03) : 640 - 651
[43] A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium
Jabbour, Elias J.
Short, Nicholas J.
Huang, Xuelin
Maiti, Abhishek
Kadia, Tapan M.
Daver, Naval
Borthakur, Gautam
DiNardo, Courtney D.
Pemmaraju, Naveen
Sasaki, Koji
Estrov, Zeev
Verstovsek, Srdan
Ravandi, Farhad
Alvarado, Yesid
Sekeres, Mikkael A.
Komrokji, Rami S.
Steensma, David P.
DeZern, Amy E.
Roboz, Gail J.
Miller, Darla
Dong, Xiao
Kantarjian, Hagop M.
Garcia-Manero, Guillermo
[J]. BLOOD, 2016, 128 (22)
[44] A phase 2/3 trial of oral azacitidine (Oral-AZA) in patients (pts) with low- or intermediate-risk myelodysplastic syndromes (MDS)
Garcia-Manero, Guillermo
Santini, Valeria
Fenaux, Pierre
Suzuki, Takahiro
Sekeres, Mikkael A.
He, Jun
Barkalifa, Ronit
Vigil, Carlos Enrique
Prebet, Thomas
Komrokji, Rami S.
Giagounidis, Aristoteles
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[45] Treatment strategies and issues in low/intermediate-1-risk myelodysplastic syndrome (MDS) patients
Bowen, DT
[J]. SEMINARS IN ONCOLOGY, 2005, 32 (04) : S16 - S23
[46] Pharmacokinetics and Exposure-Response of Luspatercept in Patients with Anemia Due to Low- or Intermediate-1-Risk Myelodysplastic Syndromes (MDS): Preliminary Results from Phase 2 Studies
Chen, Nianhang
Laadem, Abderrahmane
Wilson, Dawn M.
Zhang, Xiaosha
Sherman, Matthew L.
Ritland, Steve
Attie, Kenneth M.
[J]. BLOOD, 2016, 128 (22)
[47] Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality
Hironori Harada
Mitsumasa Watanabe
Kenshi Suzuki
Soshi Yanagita
Takahiro Suzuki
Yataro Yoshida
Akiro Kimura
Mitsuru Tsudo
Akira Matsuda
Kaoru Tohyama
Masafumi Taniwaki
Kenichi Takeshita
Masaaki Takatoku
Keiya Ozawa
[J]. International Journal of Hematology, 2009, 90 : 353 - 360
[48] Lenalidomide is active in Japanese patients with symptomatic anemia in low- or intermediate-1 risk myelodysplastic syndromes with a deletion 5q abnormality
Harada, Hironori
Watanabe, Mitsumasa
Suzuki, Kenshi
Yanagita, Soshi
Suzuki, Takahiro
Yoshida, Yataro
Kimura, Akiro
Tsudo, Mitsuru
Matsuda, Akira
Tohyama, Kaoru
Taniwaki, Masafumi
Takeshita, Kenichi
Takatoku, Masaaki
Ozawa, Keiya
[J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 90 (03) : 353 - 360
[49] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
Platzbecker, U.
Symeonidis, A.
Oliva, E.
Goede, J.
Delforge, M.
Mayer, J.
Slama, B.
Badre, S.
Gasal, E.
Mehta, B.
Franklin, J.
[J]. HAEMATOLOGICA, 2017, 102 : 484 - 484
[50] A PHASE 3 RANDOMIZED PLACEBO (PBO)-CONTROLLED DOUBLE-BLIND TRIAL OF DARBEPOETIN ALFA IN LOW OR INTERMEDIATE-1 (INT-1) RISK MYELODYSPLASTIC SYNDROMES (MDS)
Platzbecker, U.
Symeonidis, A.
Oliva, E.
Goede, J.
Delforge, M.
Mayer, J.
Slama, B.
Badre, S.
Gasal, E.
Mehta, B.
Franklin, J.
[J]. LEUKEMIA RESEARCH, 2017, 55 : S29 - S30

← 1 2 3 4 5 →